Bacillus coagulans GBI-30, 6086
Safety profile
3 studies reporting safety data
Across 3 clinical studies of Bacillus coagulans GBI-30, 6086, no specific adverse events were quantitatively reported. The probiotic was described as well tolerated in 3 studies, with no treatment-related serious or non-serious adverse events noted in the available trial reports.
Caveats: Limited evidence base; absence of reported adverse events does not establish safety. Most studies were short-term (≤8 weeks) and likely powered for efficacy rather than safety, so rare events may not be detected.
- Reduced Flatulence
- Reduced C-Reactive Protein Levels
- Reduced Nasal Congestion
- Improved Lactose Digestion
- Increased CD4+ T Cell Count
- Reduced Interleukin-1β Levels
- Reduced Abdominal Pain
- Improved Stool Consistency
- Improved Gastrointestinal Symptoms
- Reduced Tumor Necrosis Factor Alpha